Skip to main content
Log in

Haben Statine einen Stellenwert in der Osteoporosetherapie?

Are statins a useful opportunity in the treatment of osteoporosis?

  • Themenschwerpunkt „Statintherapie“
  • Published:
Wiener Medizinische Wochenschrift Aims and scope Submit manuscript

Zusammenfassung

Neben der lipidsenkenden Wirkung der Statine sind mehrere weitere günstige Effekte beschrieben. Diese lipidunabhängigen Mechanismen werden pleiotrope Effekte genannt. Besonders interessant sind diese Effekte im Zusammenhang mit der Osteoporose. Auf Grund ihres molekularen Wirkmechanismus scheinen Statine in der Lage zu sein, die Knochendichte zu erhöhen und damit das Frakturrisiko als Folge der Osteoporose zu senken. In den letzten Jahren wurden mehrere Studien mit dieser Fragestellung durchgeführt. In einigen Studien konnte eine Risikoreduktion für Frakturen gezeigt werden. Allerdings konnten diese positiven Effekte in nicht allen Untersuchungen bestätigt werden. Bei den durchgeführten Studien handelte es sich fast ausschließlich um Fallkontrollstudien. Randomisierte, kontrollierte prospektive Studien fehlen bis zum heutigen Zeitpunkt, so daß eine endgültige Klärung der Frage, ob Statine einen Stellenwert in der Osteoporosetherapie haben, nicht beantwortet werden kann. Unbestritten ist allerdings auch die Tatsache, daß diese Substanzgruppe eine interessante Option für die Zukunft darstellen könnte. Bis zu einer Therapieempfehlung ist es noch ein langer Weg, so sind Fragen wie Dosierung und Dauer der Therapie noch nicht einmal andiskutiert.

Summary

The statins do not only lower cholesterol. They may have also many other positive effects. The effects beyond lipid reduction are called pleiotropic effects. One of the most interesting points is the relationship between the statins and osteoporosis. They may stimulate bone formation and as a consequence they may reduce the risk of fracture. In the past years several studies were published concerning this topic. A number of observational studies found a decreased incidence of fractures among patients who take statins, but other studies did not. Prospective randomized controlled studies are necessary to exclude the possibility of unmeasured confounding variables. At the moment we have not enough data to give an answer to the question, if statins are a usful opportunity in the treatment of osteoporosis. What we know now is, that the statins may be an interesting drug in the future for the treatment of osteoporosis, although many things are unclear, such as the right dose or the duration of treat

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Bauer DC, Mundy GR, Jamal SA et al. Statin use, bone mass and fracture: an analysis of two prospective studies [abstract]. J Bone Mnier Res 1999;14:179.

    Google Scholar 

  2. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ: Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence für two distinct pharmocological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131–140.

    PubMed  CAS  Google Scholar 

  3. Bergstrom JD, Bostedor RG, Masarachia PJ, Rezka AA, Rodan G: Alednronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000:373:231–241.

    Article  PubMed  CAS  Google Scholar 

  4. Bjarnason NH, Riis BJ, Christianson C: The effect of fluvastatin on parameters of bone remodelling. Osteoporosis International 2001;12:380–384.

    Article  PubMed  CAS  Google Scholar 

  5. Cauley JA, Jacksaon R. Pettinger M, LaCroix A, Bauer D, Chen Z, Daugherty S, Hsia J, Lewis CE. McGowan J, McNeeley SG, Passaro M: Statin Use and Bone Mineral Density (BMD) in Older Women: The Women’s Health Initiative Observational Study (WHI-OS). J Bone Miner Res 2000; 15(suppl 1):1068.

    Google Scholar 

  6. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gorwitz JH, LaCroix AZ, Platt R: Inhibitors of hydroxy-methylglutaryl-coenzyme A reductase and risk of fracture among older woman. Lancet 2000;355:2185–2188.

    Article  PubMed  CAS  Google Scholar 

  7. Chan MH, Mak TW, Chiu RW, Chow CC, Chan I, Lam C: Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterlaemia. J Clin Enodcrinol Metab 2001;86:4556–4559.

    Article  CAS  Google Scholar 

  8. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatricl LA: HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endokrinol Metab 2000;85:1137–1142.

    Article  CAS  Google Scholar 

  9. Coxon FP, Helfrich MH, Van’t Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ: Protein geranylgeranylation is required für osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J bone Miner Res 2000:15:1467–1476.

    Article  PubMed  CAS  Google Scholar 

  10. Edwards CJ, Hart DJ, Spector TD: Oral statins and increased bone mineral density in postmenopausal women. Lancet 2000;355:2218–2219.

    Article  PubMed  CAS  Google Scholar 

  11. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA: Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 1999;96:133–138.

    Article  PubMed  CAS  Google Scholar 

  12. Goldstein JL, Brown MS: Regulation of mevalonate pathway. Nature 1990;343:425–430.

    Article  PubMed  CAS  Google Scholar 

  13. Grove JE, Brown RJ, Watts DJ: The intracellular target for the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase. J Bone Miner Res. 2000;15:971–981.

    Article  PubMed  CAS  Google Scholar 

  14. LaCroix AZ, Cauley JA, Jackson R, et al. Does statin use reduce risk of fracture in postmenopausal women? Results from the Women’s Health Initiative Oberservational Study(WHl-OS) [abstract]. J Bone Miner Res 2000:15(suppl 1):1066.

    Google Scholar 

  15. Lauf U, Böhm M, Liao JK: New findings on the action of HMG-CoA-reduktase inhibitors. Dtsch Med Wschr 1997;122:1255–1259.

    Google Scholar 

  16. Meier CR, Schlieninger RG, Kraenzlin ME, Schlegel B, Jick H: HMG-CoA-reductase inhibitors and the risk of fractures. JAMA 2000;283:3205–3210.

    Article  PubMed  CAS  Google Scholar 

  17. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G: Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946–1949.

    Article  PubMed  CAS  Google Scholar 

  18. Pasco JA, Kotowicz MA. Henry MJ, Sanders KM. Nicholson GC: Statin Use, Bone Mineral Density. Fracture Risk. Arch Intern Med 2002;162:537–540.

    Article  PubMed  CAS  Google Scholar 

  19. Federson TR. Kjekshus J: Statin drgus and the risk of fracture [letter]. JAMA 284;1921–1922.

  20. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahow S, Sharpe N: Effect of pravastatin on frequency of fracture in the LIPID-stduy: secondary analysis of a randomized controlled trial. Lancet 2001;357:509–512.

    Article  PubMed  CAS  Google Scholar 

  21. Rodan GA, Mrtin TJ: Therapeutic approaches to bone disease. Science 2000;289:1508–1514.

    Article  PubMed  CAS  Google Scholar 

  22. Stein EA, Farnier M, Waldsteicher J, Mercuri M: Effects of statins on biomarkers of bone metabolism: a randomized trial. Nutr Metab Cardiovasc Dis. 2001;2:84–87.

    Google Scholar 

  23. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S: Compactin and simvastatin, but not pravastatin, induce bone morphogenic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 2000;19;217:688–692.

    Article  Google Scholar 

  24. Van Staa TP, Wegman S, de Vries F, Laufkens B, Cooper C: Use of statins and risk of fractures. JAMA 2001;285:185o-185d.

    Google Scholar 

  25. Wang PS, Solomon DH, Mogun H, Avorn J: HMG-CoA-reductase inhibitor and the risk of hip fracture in elderly patients. JAMA 2000;283: 3211–3216.

    Article  PubMed  CAS  Google Scholar 

  26. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakamo T, Fujita T: Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 2001;110:584–587.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Markus Gösch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gösch, M. Haben Statine einen Stellenwert in der Osteoporosetherapie?. WMW 153, 255–257 (2003). https://doi.org/10.1046/j.1563-258X.2003.03030.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1046/j.1563-258X.2003.03030.x

Schlüsselwörter

Keywords

Navigation